Global Drug Based on Gene Therapy Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Drug Based on Gene Therapy Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Drug Based on Gene Therapy report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Drug Based on Gene Therapy market is projected to reach US$ 49770 million in 2029, increasing from US$ 9063.6 million in 2022, with the CAGR of 27.5% during the period of 2024 to 2029. Demand from Neurological Diseases and Cancer are the major drivers for the industry.
The Drug Based on Gene Therapy market is primarily driven by the revolutionary potential of gene therapy to address genetic disorders at their root cause, offering a new paradigm for treating previously incurable conditions. Gene therapy involves introducing genetic material into a patient's cells to correct or replace faulty genes, aiming to restore normal cellular function. The increasing understanding of the genetic basis of diseases, coupled with advancements in gene delivery methods and genome editing techniques, contributes to market growth. Moreover, the demonstrated benefits of gene therapy in providing targeted and long-lasting treatments, overcoming limitations of traditional pharmacological approaches, and offering hope to patients with rare genetic disorders further propel adoption. However, challenges include optimizing gene delivery efficiency, addressing potential immune responses, and ensuring the long-term safety and durability of gene-based treatments. Navigating regulatory pathways, conducting rigorous clinical trials, and addressing ethical considerations are ongoing concerns. The market's success relies on continuous research in genetic medicine, collaborations between biotechnology companies and research institutions, and comprehensive education on the benefits and potential challenges of using gene therapy-based drugs while addressing the evolving challenges associated with precision medicine and personalized treatments.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drug Based on Gene Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy
Neurological Diseases
Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Drug Based on Gene Therapy market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Drug Based on Gene Therapy introduction, etc. Drug Based on Gene Therapy Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Drug Based on Gene Therapy market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Drug Based on Gene Therapy report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Drug Based on Gene Therapy market is projected to reach US$ 49770 million in 2029, increasing from US$ 9063.6 million in 2022, with the CAGR of 27.5% during the period of 2024 to 2029. Demand from Neurological Diseases and Cancer are the major drivers for the industry.
The Drug Based on Gene Therapy market is primarily driven by the revolutionary potential of gene therapy to address genetic disorders at their root cause, offering a new paradigm for treating previously incurable conditions. Gene therapy involves introducing genetic material into a patient's cells to correct or replace faulty genes, aiming to restore normal cellular function. The increasing understanding of the genetic basis of diseases, coupled with advancements in gene delivery methods and genome editing techniques, contributes to market growth. Moreover, the demonstrated benefits of gene therapy in providing targeted and long-lasting treatments, overcoming limitations of traditional pharmacological approaches, and offering hope to patients with rare genetic disorders further propel adoption. However, challenges include optimizing gene delivery efficiency, addressing potential immune responses, and ensuring the long-term safety and durability of gene-based treatments. Navigating regulatory pathways, conducting rigorous clinical trials, and addressing ethical considerations are ongoing concerns. The market's success relies on continuous research in genetic medicine, collaborations between biotechnology companies and research institutions, and comprehensive education on the benefits and potential challenges of using gene therapy-based drugs while addressing the evolving challenges associated with precision medicine and personalized treatments.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drug Based on Gene Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy
Segment by Application
Neurological Diseases
Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Drug Based on Gene Therapy market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Drug Based on Gene Therapy introduction, etc. Drug Based on Gene Therapy Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Drug Based on Gene Therapy market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices